Estrogen Receptor alpha

Subscribe to Selected New Research on Estrogen Receptor alpha

1692 relevant articles (35 outcomes, 244 trials/studies) found for this Bio-Agent

Description: One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.

Also Known As:

ERalpha; Estradiol Receptor alpha; Estrogen Receptor 1; Estrogen Receptors alpha; Receptor alpha, Estrogen; Receptor alpha, Estradiol; alpha, Estradiol Receptor

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 56522

Transcription Factors: 9795

Steroid Receptors: 1428

Estrogen Receptors: 1878

Estrogen Receptor alpha: 1692

human ESR1 protein

Cytoplasmic and Nuclear Receptors: 506

Steroid Receptors: 1428

Estrogen Receptors: 1878

Estrogen Receptor alpha: 1692

human ESR1 protein

Experts

1.	Safe, Stephen: 10 articles (02/2008 - 01/2002)
2.	Davidson, Nancy E: 8 articles (06/2007 - 09/2003)
3.	Leclercq, Guy: 6 articles (09/2008 - 01/2002)
4.	Swaab, Dick F: 6 articles (11/2007 - 10/2002)
5.	Kumar, Rakesh: 6 articles (11/2006 - 10/2002)
6.	Korach, Kenneth S: 6 articles (05/2005 - 05/2002)
7.	Gustafsson, Jan-Ake: 5 articles (10/2008 - 01/2004)
8.	Nardulli, Ann M: 5 articles (09/2008 - 12/2002)
9.	Laurent, Guy: 5 articles (09/2008 - 11/2003)
10.	Uitterlinden, André G: 5 articles (04/2008 - 07/2003)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2008 - "AIM: The study aimed to establish the frequency of occurrence of Pvull and Xbal gene polymorphism of estrogen receptor alpha in a group of children and adolescents from north-eastern Poland with diagnosed and treated cancer" 10/19/2007 - "These studies establish a novel molecular site responsible for Tam- and OHT-ERalpha-induced apoptosis of cancer cells." 08/09/2007 - "Previously, microarray profiling studies determined that the highest expression of both GATA3 and ESR1 (estrogen receptor alpha) is seen in tumors associated with the most favorable survival outcomes, whereas the lowest expression of GATA3 is detected in tumor subtypes showing the worst outcomes" 03/01/2007 - "Thus, our model might provide a preclinical relevant model system to study the role of AKT and ERalpha in breast tumorigenesis and the response of mammary gland tumors to chemotherapeutics." 01/01/2006 - "Statistical analysis of the grading between the two study groups revealed no significant difference (P=0.091), although the ERalpha-PR+ group contained significantly more poorly differentiated tumors than the ERalpha+PR+ one (P=0.032)" Get all the results and reference details, order at left...
2.	Breast Neoplasms (Breast Cancer) 03/01/2002 - "We found that higher doses of AS2O3 dramatically reduced the survival of these two breast cancer cell lines while lower doses of AS2O3 significantly inhibited the expression of estrogen receptor alpha (ER-alpha), but did not effect ER-beta expression" 09/01/2008 - "Our data suggest that phosphorylation of ERalpha Ser118 and ERalpha Ser167 affects survival in ER-positive breast cancer and could be helpful in distinguishing patients who are likely to benefit from endocrine therapy alone from those who are not." 10/01/2007 - "Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients." 11/01/2008 - "CONCLUSION: Our study demonstrated genetic polymorphisms of ERalpha, CYP19A1, COMT and p53 genes frequently occur in ER-positive breast cancer in premenopausal Japanese women." 08/01/2008 - "In this study, we showed that CEACAM6 was overexpressed in a panel of oestrogen receptor (ERalpha)-positive human breast cancer cell lines (MCF-7:5C and MCF-7:2A) that have acquired resistance to oestrogen deprivation, and this overexpression was associated with a more aggressive invasive phenotype in vitro" Get all the results and reference details, order at left...
3.	Carcinoma (Carcinomatosis) 09/15/2008 - "RESULTS: To the authors' knowledge, this is the first study to report that ERalpha was phosphorylated in the plasma membrane fractions derived from patients' invasive breast carcinomas" 01/01/2007 - "This article highlights a recent study by Holst et al. in Nature Genetics that finds estrogen receptor-alpha (ER-alpha) amplification in early benign lesions and more advanced invasive carcinomas of the breast, and discusses the potential implications to our present understanding of the role of ER-alpha in breast tumorigenesis." 01/01/2008 - "CONCLUSIONS/SIGNIFICANCE: The activating signal dictates both target gene selection and regulation by ERalpha, and this has consequences on global gene expression patterns that may be relevant to understanding the progression of ERalpha-dependent carcinomas." 09/01/2007 - "Immunohistochemically, 14 of 18 carcinomas were positive for estrogen receptor alpha" 05/01/2007 - "RESULTS: In NBE adjacent to carcinoma, the positivity of ERalpha and PgR was 99% (217 out of 220) and 89% (195 out of 220), respectively" Get all the results and reference details, order at left...
4.	Neoplasm Metastasis (Metastasis) 02/01/2007 - "A significant reduction in the incidence of osteolytic bone metastasis was observed by X-ray imaging of the legs and arms of mice inoculated with ERalpha-expressing clones of MDA-MB-231 cells in comparison to controls" 06/01/2007 - "EGR3 immunoreactivity was positively associated with lymph node status, distant metastasis into other organs, estrogen receptor alpha, or EGR3 immunoreactivity in asynchronous recurrent lesions in the same patients, and was negatively correlated with tubule formation" 06/01/2005 - "IRS-1 expression in lymph node metastases correlated with neither ERalpha nor Ki-67" 05/23/2003 - "MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions." 02/01/2007 - "Our study indicates for the first time that stable reintroduction of functional ERalpha in ERalpha-negative human breast cancer cells can inhibit their aggressive bone-metastatic potential in an experimental bone metastasis model." Get all the results and reference details, order at left...
5.	Adenoma (Adenomas) 03/01/2004 - "Among the ERalpha-positive adenomas, ERalpha values were significantly greater in invasive macroadenomas (80%) than in microadenomas (3.33%)" 03/01/2004 - "ERalpha was significantly more prevalent in controls than in patients with adenomas (37.5 versus 5.7%; p = 0.001); however, the mean ERalpha concentration in adenomas was significantly greater than in controls (42.89 versus 0.024%; p < 0.001)" 03/01/2004 - "MIB-1 values did not differ significantly between ERalpha-positive and -negative adenomas, nor did the correlation between ERalpha values and the MIB-1 index attain significance in the total sample, even when only ERalpha-positive adenomas and positive MIB-1 indexes were considered" 03/01/2004 - "The presence of ERalpha was positive in 9/158 adenomas with a median value for the percentage of labeled cells of 42.89%, and in 6/16 controls (autopsy samples) with a median value for the percentage of labeled cells of 0.024%" 05/01/2005 - "Quantitative expression of both ERalpha and ERbeta by real-time RT-PCR analysis and Western blotting findings did not differ among adenoma, normal adjacent adrenal and normal adrenal control tissues" Get all the results and reference details, order at left...
273 Diseases and 1692 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Estrogens (Estrogen)
2.	Estrogen Receptor alpha
3.	Progesterone Receptors (Progesterone Receptor)
4.	Estradiol (Estrace)
5.	Paclitaxel (Taxol)
6.	Protein Isoforms (Isoforms)
7.	Estrogen Receptor beta
8.	Estrogen Receptors
9.	Estrogen Receptor Modulators (Antiestrogen)
10.	Tamoxifen
510 Drugs and Important Bio-Agents and 1295 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Adjuvant Chemotherapy
2.	Castration
3.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
4.	Drug Therapy (Chemotherapy)
5.	Heterologous Transplantation (Xenotransplantation)
18 Therapies and Procedures and 51 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>